Zydus Lifesciences gets USFDA nod to market generic drug
![Zydus Lifesciences gets USFDA nod to market generic drug](https://devdiscourse.blob.core.windows.net/devnews/16_03_2022_16_58_58_4616635.jpg)
- Country:
- India
Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to market a generic product which is used to treat myxedema coma.
The company has received the final approval for Levothyroxine Sodium for Injection in strength of 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the US Food and Drug Administration (USFDA), the drug firm said in a statement.
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma.
Zydus said the drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara (India).
Shares of the company were trading 0.19 per cent up at Rs 483.20 apiece on the BSE.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Gujarat Government Drafts New Boating Regulations After Vadodara Tragedy
6 persons killed as truck hits bus on Ahmedabad-Vadodara Expressway near Anand town in Gujarat: Police.
Hardik Pandya's Heroic Homecoming: Celebrations Galore in Vadodara
Zydus Lifesciences Gains USFDA Approval for New Diabetes Drug Zituvimet XR
USFDA Flags Zydus Lifesciences' Gujarat Facility for Regulatory Issues